The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe ...

GSK’s team developed a second-generation route for manufacturing the cancer drug maleimidocaproyl monomethyl auristatin F (mcMMAF) which reduces solvent consumption by 16,160 kg per kilogram of ...